Large COVID-19 study hints at potential benefit of experimental drug remdesivir.
However, Gilead has not yet released enough information from the trial to show what that"improvement" means for patients. The company said full results would be published"in the coming weeks."
The analysis did not compare remdesivir to a placebo, so it's impossible to determine whether any benefits were due to the drug or whether patients would have improved on their own.This latest study was meant to determine how long hospitalized patients would need to be on the drug for a potential clinical benefit. If patients only need five days of treatment, rather than 10, it would mean Gilead could double the number of people treated.
"This is particularly important in the setting of a pandemic," Dr. Merdad Parsey, Gilead's chief medical officer, said in the press release. Remdesivir is not approved by the Food and Drug Administration, and has not been proven as an effective treatment for patients with the coronavirus. Studies on the drug are ongoing, and data from a National Institute of Allergy and Infectious Diseases trial are expected later Wednesday.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Mnuchin defends $500 billion federal lending program to large corporations: WaPo - Business InsiderThe program doesn't impose significant restrictions on executive pay or worker layoffs, fueling concerns corporations will reward shareholders.
Read more »
Large crowd break lockdown to attend wedding ceremony on streets of ChicagoGroup gathered in area of Chicago which has highest number of confimred cases of COVID-19 in the city.
Read more »
Indiana postal worker dies after being shot, suspect remains at largeThe woman was talking while she was transported to hospital after the shooting in Indianapolis, but later died of her injuries.
Read more »
Large companies returning their small business loans amid backlash - Business InsiderPublicly traded companies are now required to return loans under the Paycheck Protection Program. Private ones like Sweetgreen are returning them too.
Read more »
Amid health worries, Kim Jong Un's role looms largeAs questions mount about the health of Kim Jong Un, an underlying concern looms for spies, policymakers, academics and curious news-consumers alike. What do we really know about the man who leads North Korea? By APklug .
Read more »
Lithuanian city flirts with becoming one large outdoor caféTo keep restaurants, bars and cafés afloat during the pandemic, Vilnius Mayor Remigijus Šimašius is opening up public spaces such as plazas and squares to be used for outdoor dining.
Read more »